. 

The Committee for Justice

and Recognition of Myalgic Encephalomyelitis

===============================================================================

 

Poliomyelitis and Myalgic Encephalomyelitis

Conditions irrevocably linked together by their history and

more importantly by extensive neurological similarities.

 

=====================================================================

 

THE AMERICAN JOURNAL OF MEDICINE.

  September 28, 1998, Volume 105 (3A).

 

 

Parallels Between Post-Polio Fatigue and Chronic

Fatigue Syndrome: A Common Pathophysiology ?

 

Richard L. Bruno, PhD,  Susan J. Creange, PhD,  Nancy M. Frick, LhD

 

 

Fatigue is the most commonly reported and most debilitating of post-polio sequelae affecting the >1.8 million North American polio survivors.  Post-polio fatigue is characterized by subjective reports of difficulty with attention, cognition, and maintaining wakefulness.  These symptoms resemble those reported in nearly 2 dozen outbreaks of post-viral fatigue syndromes (PVFS) that have recurred during this century and that are related clinically, historically, anatomically, or physiologically to poliovirus infections.  This article reviews recent studies that relate the symptoms of post-polio fatigue and chronic fatigue syndrome (CFS) to clinically significant deficits on neuropsychologic tests of attention, histopathologic and neuroradiologic evidence of brain lesions, impaired activation of the hypothalamic-pituitary-adrenal axis, increased prolactin secretion, and electroencephalogram (EEG) slow-wave activity.  A possible common pathophysiology for post-polio fatigue and CFS, based on the Brain Fatigue Generator Model of PVFS, and a possible pharmacotherapy for PVFS based on replacement of depleted brain dopamine, will be described.

 Am J Med. 1998;105(3A):66S-73S. ©1998 by Excerpta Medica, Inc.

________________________________________________________________________

 

 

Fatigue is the most commonly reported and most debilitating of post-polio sequelae affecting the >1.8 million North American polio survivors.  In 2 national surveys, 91% of polio survivors reported new or increased fatigue, 41% reported fatigue significantly interfering with performing or completing work, and 25% reported fatigue interfering with self-care activities.[1,2]  Fatigue was reported to be triggered or exacerbated by physical overexertion in 92% and by emotional stress in 61%.  Importantly, polio survivors differentiate between the physical tiredness and decreased endurance they associate with new muscle weakness and a "brain fatigue" that is characterized by problems with attention and cognition.  Between 70% and 96% of polio survivors reporting fatigue complained of difficulty with concentration, memory, attention, word-finding, maintaining wakefulness, and thinking clearly, with 77% reporting moderate-to-severe difficulty with these symptoms.[3]

 

These reports are reminiscent of the symptoms associated with nearly 2 dozen outbreaks during this century of Myalgic Encephalomyelitis (ME) and Chronic Fatigue Syndrome (CFS), conditions that can be related historically, clinically, anatomically, or physiologically to poliovirus infections.  These relations will be described in an attempt to suggest a possible common pathophysiology for all post-viral fatigue syndromes (PVFS).

 

POLIOENCEPHALITIS AND FATIGUE.

 

Neither the acute- nor late-onset problems with attention and cognition in polio survivors can be explained by poliovirus-induced damage to spinal motor neurons.[4]  Post-mortem histopathology performed 50 years ago demonstrated the consistent presence of poliovirus lesions in specific brain areas (Figure 1).  Brain stem centers were found to be "involved in even mild cases" of polio.[5]  The midbrain reticular formation was "always severely altered,"[6] being "heavily peppered throughout"[7-11] with lesions that were "very common and often severe."[7]  Hypothalamic, thalamic, and caudate nuclei, the putamen, and the globus pallidus were also lesioned by the poliovirus.[11,12]  Neurons in the periaqueductal gray, locus ceruleus, and especially the substantia nigra, were also damaged or destroyed by poliovirus infection.[5,8-11]

 

These findings indicate that poliovirus consistently and often severely damaged the brain areas responsible for cortical activation: the reticular formation, hypothalamus, thalamus, substantia nigra, and locus ceruleus, i.e., the reticular activating system.[13-20]  Moreover, clinical reports written during the polio epidemics corroborate the pathologic evidence of poliovirus damage to the reticular-activating system, since "drowsiness," lethargy, prolonged somnolence, rousable stupor, and even coma were described as sequelae of the acute poliovirus infection.[7,12,21,22]  Holmgren [23] reported that ³34% of patients with acute paralytic or nonparalytic poliomyelitis demonstrated "mental changes" such as "disorientation, apathy, pronounced sleep disorder, [and] irritability."  These changes were significantly correlated with abnormal slowing of the electroencephalogram (EEG) in 33% of those with paralytic or nonparalytic poliomyelitis.  Meyer [24] reported that a "high percentage of children clinically recovered from poliomyelitis insofar as motor disability is concerned, reveal qualitative difficulties in mental functioning [such as] fatigability [sic] and fleeting attention" for months after the acute episode.

 

Late-onset post-polio fatigue, myalgic encephalomyelitis, and CFS can now be compared using techniques that were unavailable during the 1950s.[25-28]  However, the historical parallels between the poliovirus and chronic fatigue should not be overlooked, since history provides its own lessons as well as a context in which new empiric data can more meaningfully be interpreted.

 

HISTORICAL PARALLELS

 

"Attenuated" Type II Poliovirus Infection

 

During the polio epidemics of the 1950s, a syndrome of impaired cortical activation and parkinsonism was attributed to the poliovirus.  In 1951, 3 cases of "drowsiness" and rousable stupor with marked slowing of the EEG, "bulbar signs," and parkinsonism were reported.[29]  Although these symptoms were atypical of polio, their occurrence in an area where poliomyelitis had become a "serious problem," and the pathologic evidence that "the main brunt of the disorder was borne by the midbrain," prompted the investigators to suggest that the syndrome might be caused by a poliovirus with "attenuated virulence."  In 1952, 8 additional patients were described having an encephalitis whose dominant features were again somnolence and extrapyramidal symptoms.[30]  Type II poliovirus was isolated from half of these patients, and the 2 fatal cases that came to autopsy had lesions in the reticular formation, hypothalamus, and substantia nigra.

 

The association of poliovirus-induced somnolence with extrapyramidal symptoms highlights the prominence of poliovirus lesions in the basal ganglia and importance of the basal ganglia in maintaining cortical activation.[31,32]  The basal ganglia are thought to gate "sensory input" to the thalamus,[32] with the putamen said to control the "mechanisms that contribute to selective attention."[33]  Putamen-lesioned animals are "insensitive to quite gross visual stimuli" and "clearly [demonstrate] difficulty transferring attention.[34]

 

In humans, basal ganglia lesions and impairment of dopaminergic input to the striatum decrease both the diffuse activation of the cortex [35] and the ability to "maintain targeted attention."[36]  For example, Parkinson's disease patients demonstrate not only an impaired ability to "transfer attention,"[37] but also marked fatigue.[38,39]  "Excessive fatigue" was reported in another study by 48% of Parkinson's disease patients,[40] fatigue that was associated with abnormal glucose metabolism or blood flow in the putamen and supplementary motor area (cf. the Brain Fatigue Generator Model, below).  It is noteworthy that one of the first descriptions of cognitive dysfunction in Parkinson's disease [41] could serve as a definition for PVFS, i.e., syndromes "characterized by a diminution of voluntary attention, spontaneous interest, initiative, and the capacity for effort and work, with significant and objective fatiguability, and a slight diminution of memory."

 

"Atypical" Poliomyelitis and Chronic Fatigue

 

Beginning in Los Angeles in 1934 and continuing for >20 years, there were over a dozen outbreaks of a disease that was at first diagnosed as poliomyelitis, then as "abortive" or "atypical" poliomyelitis, and finally named ME. [26,42]  Like poliomyelitis, initial symptoms of ME included headache, neck pain, low-grade fever, and myalgia that were often followed by paresis.  Irritability and anxiety, symptoms typical of the encephalitis accompanying bulbar polio,[22] and even a few cases of post-acute parkinsonism [42] were seen.  Patients demonstrated hypersomnolence and "conspicuous changes in their levels of concentration" that persisted for months after the acute illness.[26]  Slowing of the EEG with the emergence of theta activity, similar to that documented in polio survivors, was also noted.[23,43-45] 

 

Unlike poliomyelitis, there were frequent complaints of numbness or parasthesias, usually no respiratory involvement, infrequent paralysis or muscle atrophy, and almost invariably no fatalities.  Poliovirus was never isolated from ME patients.  Also unlike poliomyelitis, recovery from the acute symptoms of ME sometimes required months or years.[46]  Most patients were left with a marked "exhaustion and fatiguability" that were "always made worse by exercise [and] emotional stress."[26]  Patients continued to demonstrate fatigue, hypersomnolence, impaired concentration, and reported "an inordinate desire to sleep" and anomia for years after the acute episode.[26]

 

Despite the differences between poliomyelitis and ME, an association with the poliovirus was suggested by the fact that, of the >12 ME outbreaks before the introduction of the Salk vaccine, 9 occurred during or immediately after outbreaks of polio and several involved hospital staff who cared for polio patients.[42,47-53]

 

Type III Poliovirus and Iceland Disease

 

A more direct association between the poliovirus and ME was seen after a 1948 epidemic in Akureyri, Iceland.  Two patients presented with fever, myalgia, and paresis, and were at first diagnosed as having poliomyelitis.  This diagnosis was quickly discarded as many more patients reported symptoms atypical of polio, including parasthesias, numbness, "nervousness," and "general tiredness" both acutely and for months after the acute episode.  Also unlike poliomyelitis, there was a case fatality ratio of zero versus a minimum of 2.0% for polio in Iceland,[54] and poliovirus was never isolated from any of these patients. When patients were reexamined 6 years after the original outbreak, 72% reported chronic "nervousness and general tiredness," and 21% reported "loss of memory."[55]

 

Sigurdsson et al [54] suggested 2 alternatives for the cause of this constellation of symptoms, which has been called Iceland Disease: "Either a strain of poliomyelitis virus with unusual pathologic properties and of low virulence was responsible for this epidemic or ... some unknown neurotropic virus has been present."  Unbeknownst to Sigurdsson, the existence of a "low virulence" nonparalytic poliovirus, capable of lesioning the anterior cord and/or the medulla, midbrain, vagal and vestibular nuclei, reticular formation, substantia nigra, thalamus, and hypothalamus, had been demonstrated in the United States in 1947.[56]

 

Support for an "unusual" poliovirus as the cause of Icelandic Disease came 10 years later from Sigurdsson himself.[57]  There was an "extensive epidemic" of poliomyelitis caused by Type I poliovirus in Iceland during 1955 that coincided with and was followed by outbreaks of Iceland Disease.  Remarkably, 2 cities in which Iceland Disease outbreaks were reported in 1955, as well as the area affected by the 1948 Akureyri disease epidemic, were untouched by poliomyelitis.  None of the children tested in the 2 cities newly affected by Iceland Disease, and only 13% of the children in Akureyri, showed antibodies to Type I poliovirus, as opposed to 86% of the children tested in the polio epidemic areas.  Further, after poliovirus immunization, children in one of the Iceland-Disease-affected cities demonstrated antibody titres to Type II and Type III poliovirus that were 4 and 25 times higher, respectively, than titers in a city where Iceland Disease had not been reported.  The investigators concluded that Type I poliovirus was not related to the occurrence of Iceland Disease but that inhabitants of the Iceland-Disease-affected areas had previously been exposed to an agent immunologically similar to Type III poliovirus.

 

Post-Polio Fatigue and Chronic Fatigue Syndrome (CFS)

 

A constellation of symptoms resembling ME was termed CFS after a Nevada outbreak in 1984.[27]  Like ME and post-polio fatigue, CFS is characterized by complaints of chronic fatigue and impaired concentration that are triggered or exacerbated by physical exertion and emotional stress.[58]  Both CFS patients [58,59] and polio survivors [3] report subjective memory impairment and word-finding difficulty, while 85% of patients with CFS demonstrated an excess of irregular slow-wave activity on EEG [60] similar to that seen after ME and polio.[23,43-45]  In both polio survivors and CFS patients the incidence of fatigue and physical and psychological symptoms is significantly higher than in the general population (Table 1).[2,27]

 

The recent emergence of CFS has allowed it to be studied using techniques that were unavailable during the polio, ME, and Iceland Disease epidemics and that now allow physiologic comparisons between this most recent putative PVFS and post-polio fatigue.

 

Table 1.    Demographic Data, Signs, and Symptoms in Polio Survivors with Fatigue,

Patients with Chronic Fatigue Syndrome (CFS), and Non-disabled Controls

                                                Polio                    CFS

                                                Survivors              Patients        Controls

n                                              373                          259                   145

Age                                           54(±11)*                 38(±11)*$        47(±14)

Female/male ratio                    1.5                           2.1                    1.5

Working full time                  40%$                       43% $               59%

Fatigue                                     91%$                     100%*$              15%

Difficulty concentrating        96%                         82%*                 n/a

Muscle pain                             72%$                       85%*$              15%

Anxiety                                    69%$                       71% $               36%

Depressed mood                      57%$                       68%*$              41%

Headaches                               32%$                       58%*$              15%

Diarrhea                                  10%$                       36%*$                2%

n/a = not ascertained.  Significantly different (p <0.01) as compared to polio survivors (*) or controls ($) by independent-groups t test or chi-square.   CFS data from Ann Intern Med [27]; polio survivors' and control data from Research and Clinical Aspects of the Late Effects of Poliomyelitis [2] and Orthopedics. [3]

 

Table 2.   Demographic and Neuropsychologic Data (mean ± standard deviation) in Polio Survivors Reporting Low and High Fatigue and in Patients with Chronic Fatigue Syndrome (CFS)

                                                                .   Polio Survivors  A   .              

                                                                 Low                        High                         CFS

                                                                Fatigue                  Fatigue                  Patients

Age (years)                                               51 (12)                      44 (4)                        37 (9) C

Years of education                                      15 (3)                        14 (4)                        16 (2) C

Beck Depression Inventory Score                13 (7)                        14 (2)                        15 (3) B

I.Q.                                                          111 (2)                      111 (1)                      111 (4) B

Memory tests

  WMS-R Logical Memory:

       Immediate Recall                                 23 (3)                        32 (6)                        26 (7) C

       Delayed Recall                                    14 (9)                        28 (8)                        21 (8) C

  WMS-R Visual Reproduction:

       Immediate Recall                                 32 (7)                        34 (7)                        34 (4) C

       Delayed Recall                                    16 (3)F                      16 (9)F                      29 (6) C

Attention tests

  Trail Making Test:

       A (seconds)                                        21 (3)                        35 (13)F                    34 (12) D

       B (seconds)                                        48 (9)                        62 (6)                        76 (35) D

  Paced Auditory Serial Addition

               Test (% correct):

       2.4/second                                          88 (11)                      55 (29)F                    39 (5) B,F

       2.0/second                                          73 (6)                        56 (23)F                    32 (5) B,F

       1.6/second                                          67 (17)                      45 (27)F                    28 (4) B,F

  Word fluency (no. words/60 seconds)

        Animal Naming                                  23 (4)                        18 (6)                        19 (5) E

        FAS                                                 43 (11)                      40 (11)                      41 (14) E

    A  -  Data from Arch Phys Med Rehabil [25] and Bruno [103]

     B  -  Data from Arch Nerurol [61]

     C  -  Data from J Neurol Neurosurg Psychiatry [64]

     D  -  Data from Biol Psychiatry [62]

     E  -  Data from Biol Psychiatry.[104]

     F  -  Clinical impaired score.

 

 

EMPIRIC PARALLELS

 

Neuropsychoiogical Parallels

 

Some of the subjective difficulties with attention and cognition in CFS patients and polio survivors have been corroborated by the documentation of clinical abnormalities on neuropsychological testing.  CFS patients [61,62] and polio survivors with severe fatigue [25] have clinical impairments of attention and information processing speed (Table 2).    Despite these marked impairments of attention, CFS patients [59] and polio survivors [2,25,63] have been shown to be within the high normal or superior range on measures of higher-level cognitive processes and intelligence quotient (IQ), as well as having higher-than-average levels of professional achievement.

 

These findings indicate that chronic fatigue is associated with impairments of attention and information processing speed, but not of verbal memory or higher-level cognitive processes, both in patients with CFS and in polio survivors.  Given the histopathologic documentation of poliovirus lesions in the brain's activating system, it was hypothesized that reticular-activating system and basal ganglia damage are responsible for fatigue and impaired attention in polio survivors.

 

Neuroanatomic Parallels

 

To test this hypothesis, magnetic resonance imaging (MRI) of the brain was performed in hope of documenting poliovirus lesions in the reticular-activating system and basal ganglia.[65]  Areas of hyperintense signal in gray and white matter were imaged in 55% of subjects who rated their daily fatigue as moderate or higher, but hyperintensities were not seen in any of the subjects reporting no or mild daily fatigue.  Small discrete areas of hyperintense signal were imaged in the putamen and rostral reticular formation.  Multiple punctate areas of hyperintense signal were imaged in the periventricular and deep white matter and discrete areas of hyperintense signal were seen in the centrum semiovale.  The presence of hyperintense signal was significantly correlated with fatigue severity, year of acute polio, and years since polio, but not with depressive symptoms, new respiratory problems, or difficulty sleeping.  The presence of hyperintense signal was also significantly correlated with the frequency or severity of subjective difficulty with recent memory, thinking clearly, mind wandering, attention, and concentration.

 

These data support the hypothesis that areas of hyperintense signal are associated with late-onset fatigue and subjective problems with attention in polio survivors and may represent poliovirus damage within the brain activating system.  Damage to the putamen and caudate nucleus [16-18] and especially the reticular formation [66] has been shown in other populations to cause deficits in attention.  The hyperintense signal imaged in the reticular formation and basal ganglia most likely indicate areas of necrosis where neurons were destroyed by the acute poliovirus infection.  This conclusion is supported by a recent case of vaccine-related poliomyelitis in which hyperintense signal in the midbrain and medulla on antemortem MRI corresponded with histopathologic findings of necrosis in the substantia nigra and reticular formation.[67]

 

Hyperintense signals imaged along white matter tracts that have been implicated in the centrifugal spread of the poliovirus [68,69] may have resulted from damage to the brain parenchyma by a local tissue toxic effect of the poliovirus causing enlarged, fluid-filled spaces around arterioles,[7] local neuronal atrophy,[69,70] and possibly axonal demyelination.[10,11]

 

Diffuse atrophy and demyelination of axons within corticofugal white matter tracts could conceivably impair transmission, decrease cortical activation, and cause attention deficits and other symptoms of fatigue.  This notion is supported by studies that have documented a relation between hyperintense signal, impaired attention, and fatigue.  First, periventricular and deep white (but not gray) matter hyperintense signals have been imaged in 27-100% of CFS patients and have been suggested to represent either enlarged, fluid-filled spaces around arterioles or demyelination.[17,70,71]  Second, white matter hyperintense signal imaged in both demented [72,73] and non-demented [74-76] elderly adults has also been associated with impairments of attention and information processing speed similar to those documented in CFS patients and polio survivors with fatigue.  Third, patients with fatigue secondary to multiple sclerosis have been found to have more brain stem and midbrain white matter hyperintense signal as well as decreased glucose metabolism on positron emission tomography (PET) in cortical premotor and supplementary motor areas and in the putamen [77] --findings similar to abnormalities in the supplementary motor area and putamen in Parkinson's disease patients with fatigue [40] (see the Brain Fatigue Generator [BFG] Model, below).  These finding implicate both damage to the reticular activating system and basal ganglia, as well as a partial disconnection between the reticular activating system, basal ganglia, thalamus, and cortex, as underlying symptoms of fatigue (Figures 2 and 3).

 

Neuroendocrine Parallels

 

The correlation of hyperintense signal on MRI with the symptoms of post-polio fatigue suggested that the effects of poliovirus on other brain centers might also be evident.  The documentation of hypothalamic lesions on autopsy after poliovirus infection suggested that neuroendocrine abnormalities may also be present.

 

For example, lesions in the paraventricular nucleus were frequently documented after poliovirus infection [68] and could impair this nucleus' ability to secrete corticotropin-releasing hormone,[78] thereby decreasing adrenocorticotropic hormone (ACTH) release.[79]

 

To examine the relation between hypothalamic-pituitary-adrenal axis activity and the symptoms of post-polio fatigue, polio survivors had their plasma concentrations of ACTH measured using radioimmunoassay after a mild stressor (an overnight fast) that is known to stimulate the hypothalamic-pituitary-adrenal axis.[80,81]  Mean plasma ACTH was significantly elevated and outside of the normal range, as it should be after an overnight fast, in subjects reporting mild daily fatigue (28.5 ± 17.7 ng/mL) but not in those reporting moderate or higher fatigue (19.7 ± 10.7 ng/mL) (t = 2.02; P <0.05).  Further, plasma ACTH was significantly negatively correlated with the daily fatigue severity rating, the frequency of problems with recent memory, word-finding, and muscle weakness, and the severity of problems with recent memory and staying awake during the day, but not with the Beck Depression Inventory score.

 

These data suggest that the response of the hypothalamic-pituitary-adrenal axis to a fasting stressor is blunted in polio survivors reporting fatigue.  This finding, coupled with histopathologic evidence of poliovirus lesions in the paraventricular nucleus, suggested that the hyposecretion of ACTH may be secondary to decreased production of the hypothalamic secretagogues corticotropin-releasing hormone and vasopressin, whose cell bodies are located in the paraventricular nucleus.[78]  Further, the significant negative correlations between ACTH level and fatigue severity, cognitive problems, and difficulty staying awake suggest that a diminution in hypothalamic-pituitary-adrenal hormones may contribute to the symptoms of post-polio fatigue.  An existing study demonstrated that decreased levels of corticotropin-releasing hormone and ACTH are associated with fatigue and impaired attention, since both peptides exert "stimulatory effects on biochemical and electrophysiologic parameters of the brain."[79,82]  In humans, administration of ACTH fragments lacking adrenal-stimulating activity was associated with improved memory and alertness, "EEG arousal response patterns," increased sustained attention,[83] and a "statistically significant fall in fatigue."[84]  These results were attributed to the direct activation of ACTH receptors on neurons in the hypothalamus, midbrain,[85] and "the brain stem, particularly the nonspecific reticular-thalamic system."[85,86]  Thus, post-polio fatigue may be attributable to poliovirus lesions not only in the reticular activating system and basal ganglia but also in the paraventricular nucleus, which decreases the secretion of peptides that cause cortical stimulation.  Decreased hypothalamic-pituitary-adrenal activity has already been documented in patients with CFS, and the decreased secretion of "activating" peptides such as corticotropin-releasing hormone and ACTH has been implicated in its pathophysiology.[87,88]

 

THE BRAIN FATIGUE GENERATOR MODEL OF PVFS

 

Taken together, the clinical, historical, and empirical findings presented above suggested the BFG model of post-polio fatigue and PVFS (Figure 2).  The BFG model postulates that viral damage to the reticular formation, lenticular, hypothalamic and thalamic nuclei, cortical motor areas, and especially dopaminergic neurons in the substantia nigra and arcuate nucleus, decrease cortical activation, not only impairing attention and slowing information processing speed, but also inhibiting motor activity and generating the disabling visceral feelings of fatigue: exhaustion, passivity, and an aversion to effort (Figure 3).[89]  The operation and survival value of a hardwired, autonomic, and normal BFG that inhibits motor activity when cortical activation, attention, and information processing speed are impaired is described fully by Bruno et al.[89]

 

Recent studies support the BFG model as an explanation for PVFS.  Two studies using thallium-201 single-photon emission computed tomography (SPECT) have documented that decreased brain stem metabolism --and by inference decreased activity of reticular activating system neurons-- was the only physiologic finding differentiating subjects with CFS from healthy controls and subjects with depression or neurologic disease.[90,91]

 

Fainting and Fatigue

 

Other studies have provided additional support for the BFG model as an explanation for post-polio fatigue as well as suggesting that decreased dopamine secretion may play a role in the generation of fatigue symptoms.

 

Reports of neurally mediated hypotension and symptomatic orthostatic tachycardia syndrome in CFS patients suggest that there may be an association between fainting and chronic fatigue.[92-94]  The brain fatigue generator model predicts such an association, not just in CFS patients but especially in polio survivors.  The brain stem area most frequently and severely lesioned by the polio-virus and other viral encephalitides was the reticular formation, which is not only responsible for cortical activation, waking, and focusing attention, but also contains the cardiodepressor center whose outflow slows the heart via stimulation of the vagus nerve.[95,96]  Near the reticular formation in the brain stem lie other cardiovascular control centers, all of which were also damaged by the polio-virus: the dorsal vagal nucleus, responsible for slowing the heart and activating the gut, and the nucleus ambiguus and solitary tract nuclei which regulate blood pressure.  Acutely, patients with bulbar polio, in which damage to brain stem neurons was most severe, demonstrated not only respiratory impairment, rousable stupor, somnolence, and even coma, but also cardiovascular abnormalities.  Cardiodepressor-center abnormalities were the more frequent symptoms, with 73% demonstrating hypertension and tachycardia.[22,97]

 

To test the hypothesis that fatigue is associated with fainting, the 1995 International Post-Polio Survey asked 1,047 polio survivors and 419 nondisabled control subjects about the frequency and cause of faints during their lifetimes and to rate their current typical daily fatigue severity.[95]  Fatigue severity was not only significantly higher in polio survivors as compared with controls, but also higher in polio survivors and controls who had fainted even once, as compared with those who had never fainted.  Daily fatigue severity also increased in both groups as the number of lifetime faints increased.  These findings suggest a physiologic relation between fatigue and fainting, possibly attributable to the close proximity of cardiovascular regulation and brain activation centers within the brain stem.  Therefore, fatigue and hypotension in patients with CFS and in polio survivors with late onset fatigue may be a symptom of damage to reticular formation neurons and not a primary cause of fatigue.

 

Hypothalamic abnormalities in polio survivors and CFS patients may also contribute to a relation between fatigue and fainting.  Corticotropin-releasing hormone release may be impaired secondary to paraventricular nucleus damage in polio survivors and CFS patients.[81,88]  Since the paraventricular nucleus also produces vasopressin, the secretion of which is impaired in CFS,[98] paraventricular nucleus damage in polio survivors and CFS patients may decrease both brain-activating and blood pressure-regulating hormones, thereby reinforcing reticular formation and BFG abnormalities and predisposing these patients to both fatigue and fainting.

 

EEG Slowing, Prolactin, and Fatigue

 

The postmortem documentation of reticular activating system and dopaminergic neuron lesions in polio survivors, the recent SPECT findings of decreased brain stem neuron activation in CFS patients, and impaired attention in post-polio fatigue and CFS, all suggest that decreased cortical activation and a dopamine deficiency may underlie the symptoms of chronic fatigue.  If there is a dopamine deficiency in polio survivors it should be physiologically evidenced by elevated levels of prolactin, since dopaminergic neurons in the arcuate nucleus were damaged by the poliovirus and arcuate dopamine secretion inhibits prolactin release via dopamine-2 (D2) receptor stimulation.[99]  Therefore, elevated prolactin should be associated with impaired cortical activation as evidenced by slowing of the EEG, since even in healthy subjects, EEG slowing is indicative of impaired cortical activation and has been associated with decreased arousal, "drowsiness," and impaired performance on neuropsychological tests of attention.[100,101]  Furthermore, as many as 85% of CFS patients have been shown to have an excess of irregular slow wave activity on EEG,[43-45,60] similar to the theta and delta activity seen in patients with acute paralytic and nonparalytic polio.[23]

 

To test the hypothesis that fatigue, prolactin, and EEG slowing are associated with post-polio fatigue, polio survivors had resting measurements of plasma prolactin and power across the EEG frequency spectrum.[102]  Prolactin levels were within the normal range and EEG power was equal between the 2 hemispheres across all frequency bands.  However, EEG slow-wave power in the right hemisphere (measured with eyes open) was significantly correlated with daily fatigue severity and prolactin level (r = 0.37; P <0.05), and prolactin was significantly correlated (r = 0.39; P <0.05) with daily fatigue severity.

 

These data suggest that EEG slowing is related to the severity of post-polio fatigue symptoms, findings similar to those in patients with acute polio and CFS.  An important role is also suggested for a dopamine deficiency, implied by the correlation of EEG power and fatigue severity with prolactin.  A recent study further supports the putative relation between decreased dopamine secretion, and symptoms of post-polio fatigue.  An objective measure of word-finding difficulty (animal naming) was significantly correlated not only with subjective word-finding difficulty (r = -0.41; P <0.05) but also with plasma prolactin (r = -0.36; P <0.05) and scores on 2 neuropsychologic tests of attention.[103]  Notably, the animal-naming score in polio survivors with fatigue was nearly identical to that in patients with CFS (Table 2).[104]

 

Bromocriptine and Fatigue

 

To test the hypothesis that treating the putative dopamine deficiency will decrease the symptoms of post-polio fatigue, a double-blind, placebo-controlled pilot study of bromocriptine mesylate, a direct-acting, postsynaptic D2 receptor agonist, was performed in polio survivors disabled by severe, chronic fatigue.[105]  Patients were placed on placebo for 28 days and then on an increasing dose of bromocriptine (1.25-12.5 mg/day) for 28 days.  Days on bromocriptine, but not days on placebo, were significantly negatively correlated with subjective difficulty with fatigue on awakening, attention, cognition, word-finding, memory, and staying awake during the day.

 

That decreased dopamine secretion contributes to the symptoms of chronic fatigue is supported by a placebo-controlled study of healthy subjects who were administered remoxipride, a potent and selective D2 receptor antagonist.[106]  The most frequently reported effects of D2 receptor blockade were "moderate fatigue," "mild somnolence," and "difficulty concentrating."  Statistically significant, dose-related increases in subjective "drowsiness" and impairment on neuro-psychological tests of auditory vigilance, continuous attention, and critical flicker fusion were also found after D2 receptor blockade.

 

CONCLUSIONS

 

These data suggest that polioviruses may be the prototypes for chronic fatigue-producing agents, since they routinely and often preferentially damage neurons responsible for brain activation and the BFG.  Post-polio fatigue may provide a complete model for a postviral fatigue syndrome, since the causative agent is known, the damage done by the agent to the brain has been demonstrated, and the signs of that damage  -- neuroanatomic, neuropsychologic, neuro-endocrinologic, and electroencephalographic --  have been documented and correlated with the symptoms of fatigue.

 

However, polioviruses are not the only agents for which the brain's activating system is the "favorite location."  Lesions in the reticular formation, putamen, thalamus, hypothalamus, and white matter have been associated with a variety of viral encephalitides whose symptoms include markedly impaired cortical activation and fatigue (e.g., Australian X, Coxsackie, Equine, Japanese B, and St. Louis infections).[26-28,107-110]  Some CNS viral infections are histopathologically and clinically similar to, or actually indistinguishable from, poliovirus infection (e.g., Central European encephalomyelitis and Coxsackie A9, Coxsackie B1-6, ECHO, Enterovirus 70 and 71 infections).  The Coxsackie A7 virus produces a paralytic syndrome so similar to that caused by the polioviruses it has been named poliovirus IV.[26-28,107-113]

 

So, whereas post-polio fatigue may present a neat and complete pathophysiologic model for PVFS, clinicians and researchers must remember that the polioviruses are neither alone nor unique in their ability to damage the spinal cord and brain, impair the reticular activating system and basal ganglia, disrupt the BFG, and generate chronic fatigue symptoms.  Given the ubiquity of viruses that can impair brain activation, the existence of PVFS should be expected. Yet, clinicians often refuse to believe that there could be a syndrome with a physiologic basis that has fatigue as its principal symptom.  However, the research reviewed in this article suggests that the practitioners in the disparate disciplines who are studying PVFS should focus less on who is right about the etiology of chronic fatigue, and focus instead on what may be wrong in the brain and how brain abnormalities causing fatigue symptoms can be treated.

 

_____________________________________________

 

From the Kids' Fatigue Management Program and The Post-Polio Institute, Englewood Hospital and Medical Center, Englewood, New Jersey;  and Harvest Center, Hackensack, New Jersey.

 

ACKNOWLEDGMENT

This article is dedicated to the memory of Dr. David Bodian, whose pioneering work describing the pathophysiology of polioencephalitis appeared in this Journal in 1949.

 

This research was supported by grants from the George A. Ohl, Jr, Infantile Paralysis Foundation.

Requests for reprints should be addressed to Richard L. Bruno, PhD, The Post-Polio Institute, Englewood Hospital and Medical Center, 350 Engle Street, Englewood, NJ 07631

 

-------------------------- REFERENCES  --------------------------

 

1. Parsons PE.  National Health Interview Survey. Washington, DC: National Center for Health Statistics, 1989.

2. Bruno RL, Frick NM.  Stress and Type A behavior as precipitants of post-polio sequelae. In: Halstead LS, Wiechers DO, eds. Research and Clinical Aspects of the Late Effects of Poliomyelitis. White Plains, NY: March of Dimes Research Foundation, 1987.

3. Bruno RL, Frick NM, Cohen J.  Polioencephalitis, stress and the etiology of post-polio sequelae. Orthopedics. 1991;14:1269-1276.

4. Trojan D, Gendron, Cashman NR.  Electrophysiology and electrodiagnosis of the post-polio motor unit. Orthopedics. 1991;14:1353-1361.

5. Bodian D.  Poliomyelitis: neuropathologic observations in relation to motor symptoms. JAMA. 1947;134:1148-1154.

6. Guizetti HU.  Betrachtungen zur poliomyelitis des hirnstammes. Deutsch Ztschr f Nervenh. 1933;131:29-42.

7. Bodian D.  Histopathological basis of clinical findings in poliomyelitis.  Am J Med. 1949;6:563-578.

8. Barnhart M, Rhines R, McCarter JC, Magoun HW.  Distribution of lesions of the brain stem in poliomyelitis.  Arch Neurol Psychiatry. 1948;59:368-377.

9. Matzke HA, Baker AB.  Poliomyelitis: a study of the midbrain.  Arch Neurol Psychiatry. 1951;65:1-15.

10. Peers JH.  The pathology of convalescent poliomyelitis in man.  Am J Pathol. 1942;19:673-695.

11. Luhan JA.  Epidemic poliomyelitis: some pathological observations on human material.  Arch Pathol. 1946;42:245-260.

12. Howe HA, Bodian D.  Neural Mechanisms of Poliomyelitis.  New York: The Commonwealth Fund, 1942.

13. Morruzi G, Magoun HW.  Brain stem reticular formation and activation of the EEG.  EEG Clin Neurophysiol. 1949;1:455-473.

14. Bentivoglio M, Steriade M.  Brainstem-diencephalic circuits as a structural substrate of the ascending reticular activation concept.  In: Mancia M, Marini G, eds. The Diencephalon and Sleep. New York: Raven Press, 1990.

15. Sakai K, El Mansari M, Lin JS, et al.  The posterior hypothalamus in the regulation of wakefulness and paradoxical sleep.  In: Mancia M, Marini G, eds. The Diencephalon and Sleep. New York: Raven Press, 1990.

16. Mesulam M-M.  Attention, confusional states, and neglect.  In: Mesulam M-M, ed. Principles of Behavioral Neurology. Philadelphia: Davis, 1985.

17. Pribram KH, McGuinness D.  Attention and para-attentional processing: event-related brain potentials as tests of a model.  Ann NY Acad Sci. 1992;658:65-92.

18. Jones BE.  Influence of the brainstem reticular formation, including intrinsic mono-aminergic and cholinergic neurons, on forebrain mechanisms of sleep and waking.  In: Mancia M, Marini G, eds. The Diencephalon and Sleep. New York: Raven Press, 1990.

19. Robbins TW.  Psychopharmacological and neurobiological aspects of the energetics of information processing.  In: Hockey GRJ, Gaillard AWK, Coles MGH, eds.  Energetics and Human Information Processing. Dordrecht: Martinus Nijhoff, 1986.

20. Mandell AJ.  Toward a psychobiology of transcendence.  In: Davidson JM, Davidson RJ, eds. The Psychobiology of Consciousness. New York: Plenum, 1980.

21. Brown JR, Baker AB, McQuarrie I, et al.  The bulbar form of poliomyelitis.  JAMA. 1947;135:425-428.

22. Baker AB.  Neurologic signs of bulbar poliomyelitis. In: Poliomyelitis. Philadelphia: Lippincott, 1949.

23. Holmgren BE.  Electro-encephalography in poliomyelitis. In: Poliomyelitis. Philadelphia: Lippincott, 1952.

24. Meyer E.  Psychological considerations in a group of children with poliomyelitis.  J Pediatrics. 1947;31:34-48.

25. Bruno RL, Galski T, DeLuca J.  Neuropsychology of post-polio fatigue.  Arch Phys Med Rehabil. 1993;74:1061-1065.

26. Behan PO, Behan WMH.  Postviral fatigue syndrome.  Crit Rev Neurobiol. 1988;4:157-178.

27. Buchwald D, Cheney PR, Peterson DL, et al.  A chronic illness characterized by fatigue neurologic and immunologic disorders and active human herpesvirus type 6 infection.  Ann Intern Med. 1992;116:103-113.

28. Hyde BM.  Myalgic encephalomyelitis (chronic fatigue syndrome): an historical perspective.  In: Hyde BM, Goldstein J, Levine P, eds. The Clinical and Scientific Basis of Myalgic Encephalomyelitis/Chronic Fatigue Syndrome. Ottawa, Ontario: The Nightingale Research Foundation, 1992.

29. Bickerstaff ER, Cloake PCP.  Mesencephalitis and rhombencephalitis.  BMJ. 1951;2:77-81.

30. Barrett AM, Gardner D, McFarlan AM.  An outbreak of encephalitis, possibly due to poliomyelitis virus. BMJ. 1952;1:1317-1322.

31. Magoun HW.  Poliomyelitis. Philadelphia: Lippincott, 1949:250.

32. Duvoisin RC, Yahr MD.  Encephalitis and parkinsonism.  Arch Neurol. 1965;12:227-239.

33. Heilman KM, Voeller KKS, Nadeau SE.  A possible pathophysiologic substrate of attention deficit hyperactivity disorder.  J Child Neurol. 1991;6(suppl):S74-S79.

34. Denny-Brown D, Yanagisawa N.  The role of the basal ganglia in the initiation of movement.  In: Yahr MD, ed. The Basal Ganglia. New York: Raven Press, 1976.

35. Owen AM, Roberts AC, Hodges JR, et al.  Contrasting mechanisms of impaired attentional set-shifting in patients with frontal lobe damage or Parkinson's disease.  Brain. 1993;116:1159-1175.

36. Echiverri HC, Tatum WO, Merens TA, Coker SB.  Akinetic mutism.  Pediatr Neurol. 1988;4:228-230.

37. Bowen FP.  Behavioral alterations in patients with basal ganglia lesions.  Res Publ Assoc Res Nerv Ment Dis. 1976;55:169-180.

38. Brown RG, Marsden CD.  Cognitive function in Parkinson's disease.  TINS. 1990;1:21-28.

39. van Hilten JJ, Hoogland G, van der Velde EA, et al.  Diurnal effects of motor activity and fatigue in Parkinson's disease.  J Neurol Neurosurg Psychiatry. 1993;56:874-877.

40. Friedman J, Friedman H.  Fatigue in Parkinson's disease.  Neurology. 1993;43:2016-2018.

41. Naville F.  Encephale. 1922;17:369-375.

42. Acheson ED.  The clinical syndrome variously called benign myalgic encephalomyelitis, Iceland disease and epidemic neuromyasthenia.  Am J Med. 1959;26:569-595.

43. Ramsay AM, O'Sullivan E.  Encephalomyelitis simulating poliomyelitis.  Lancet. 1956;i:762-767.

44. Galpine JF, Brady C.  Benign myalgic encephalomyelitis.  Lancet. 1957;i:757-758.

45. Daikos GK, Garzonis S, Paleologue A, et al.  Benign myalgic encephalomyelitis.  Lancet. 1959;i:693-696.

46. Hyde BM, Bergman S.  Chronic aspects of Akureyri Disease.  In:Jenkins R, Mowbray JF, eds. Post-Viral Fatigue Syndrome. Chichester: John Wiley & Sons, 1991.

47. Macrae AD, Galpine JF.  An illness resembling poliomyelitis observed in nurses.  Lancet. 1954;ii:350-352.

48. Gilliam AG.  Epidemiological study of an epidemic, diagnosed as poliomyelitis, occurring among the personnel of the Los Angeles County General Hospital during the summer of 1934.  US Public Health Bull. 1938;240:1-90.

49. Gsell VO.  Abortive poliomyelitis.  Helvetica Medica Acta. 1949;3/4:169-183.

50. Fog T.  Vegetative (epidemic?) neuritis.  Ugeskr Laeg. 1953;115:1244-1248.

51. Pellew RA.  Clinical description of a disease resembling poliomyelitis seen in Adelaide.  Med J Aust. 1951;1:944-946.

52. White DN, Burtch RB.  Iceland Disease: a new infection simulating acute anterior poliomyelitis.  Neurology. 1954;4:506-516.

53. Deisher JB.  Benign myalgic encephalomyelitis (Iceland Disease) in Alaska.  Northwest Med. 1957;56:1451-1456.

54. Sigurdsson B, Sigurjonsson J, Sigurdsson HJ, et al.  A disease epidemic in Iceland simulating poliomyelitis.  Am J Hyg. 1950;52:222-238.

55. Sigurdsson B, Gudmundsson KR.  Clinical findings six years after outbreak of Akureyri Disease.  Lancet. 1957;i:766-767.

56. Sabin AB, Steigman A.  Poliomyelitis virus of low virulence in patients with epidemic summer grippe or sore throat.  Am J Hygiene. 1949;49:176-193;  cf.  Bodian D, Howe HA.  Experimental nonparalytic poliomyelitis: frequency and range of pathological involvement.  Bull Johns Hopkins Hosp 1945;76:1-16.

57. Sigurdsson B, Gudnadottir M, Petursson G.  Response to poliomyelitis vaccination.  Lancet. 1958;i:370-371.

58. Hyde BM, Jain A.  Clinical observations of central nervous system dysfunction in post-infectious, acute onset ME/CFS. In: Hyde BM, Goldstein J, Levine P, eds.  The Clinical and Scientific Basis of Myalgic Encephalomyelitis/Chronic Fatigue Syndrome. Ottawa, Ontario: The Nightingale Research Foundation, 1992.

59. Altay HT, Toner BB, Brooker H, et al.  The neuropsychological dimensions of postinfectious neuromyesthenia.  Int J Psychiatry Med. 1990;20:141-149.

60. Jamal GA.  Evidence for organic disturbance in post viral fatigue syndrome.  In: Hyde BM, Goldstein J, Levine P, eds. The Clinical and Scientific Basis of Myalgic Encephalomyelitis/Chronic Fatigue Syndrome. Ottawa, Ontario: The Nightingale Research Foundation, 1992.

61. DeLuca J, Johnson SK, Natelson BH.  Information processing efficiency in chronic fatigue syndrome and multiple sclerosis   Arch Neurol. 1993;50:301-304.

62. Sandman CA, Barron JL, Nackoul K, et al.  Memory deficits associated with chronic fatigue immune dysfunction syndrome.  Biol Psychiatry. 1993;33:618-623.

63. Lonnberg F.  Late onset polio sequelae in Denmark.  Scand J Rehab Med. 1993;(suppl)28:1-32.

64. Graffman J, Schwartz V, Dale JK, et al.  Analysis of neuropsychological functioning in patients with chronic fatigue syndrome.  J Neurol Neurosurg Psychiatry. 1991;56:684-689.

65. Bruno RL, Cohen J, Galski T, Frick NM.  The neuroanatomy of post-polio fatigue.  Arch Phys Med Rehabil. 1994;75:498-504.

66. Parasuraman R, Nestor P.  Energetics of attention and Alzheimer's disease.  In: Hockey GRJ, Gaillard AWK, Coles MGH, eds. Energetics and Human Information Processing. Dordrecht: Martinus Nijhoff, 1986.

67. Wasserstrom R, Mamourian AC, McGary CT, Miller G.  Bulbar poliomyelitis: MR findings with pathological correlation.  AJNR Am J Neuroradiol. 1992;13:371-373.

68. Howe HA, Bodian D.  Neuropathological evidence on the portal of entry problem in human poliomyelitis.  Bull Johns Hopkins Hosp. 1941;69:183-214.

69. Bodian D, Howe HA.  Neurotropism and the genesis of cerebral lesions in poliomyelitis.  Bull Johns Hopkins Hosp. 1941;68:58-76.

70. Kirkpatrick JB, Hayman LA.  White-matter lesions in MR imaging of clinically healthy brains of elderly subjects: possible pathological basis.  Radiology. 1987;162:509-511.

71. Daugherty SA, Henry BE, Peterson DL, et al.  Chronic fatigue syndrome in northern Nevada.  Rev Infect Dis. 1991;13(suppl 1):S39-S44.

72. Almkvist O, Wahlund L-O, Anderson-Lundman G, et al.  White-matter hyperintensity and neuropsychological functions in dementia and healthy aging.  Arch Neurol. 1992;49:626-632.

73. Kertesz A, Polk M, Carr T.  Cognition and white matter changes on magnetic resonance imaging in dementia.  Arch Neurol. 1990;47:387-391.

74. Austron MG, Thompson RF, Hendrie HC, et al.  Foci of increased T2 signal intensity in MR images of healthy elderly subjects: a follow-up study.  J Am Geriatr Soc. 1990;38:1133-1138.

75. Boone KB, Miller BL, Lesser IM, et al.  Neuropsychological correlates of white-matter lesions in healthy elderly subjects.  Arch Neurol. 1992;49:549-554.

76. Junque C, Pujol J, Vendrell P, et al.  Leuko-araiosis on magnetic resonance imaging and speed of mental processing.  Arch Neurol. 1990;47:151-156.

77. Roelcke U, Kappos L, Lechner-Scott J, et al.  Reduced glucose metabolism in the frontal cortex and basal ganglia of multiple sclerosis patients with fatigue.  Neurology. 1997;48:1566-1571.

78. Petrusz P, Merchenthaler I.  The corticotropin-releasing factor system.  In: Nemeroff CB, ed. Neuroendocrinology. Boca Raton, FL: CRC Press, 1992.

79. Meyerhoff JL, Mougey EH, Kant GJ.  Paraventricular lesions abolish the stress-induced rise in pituitary cyclic AMP and attenuate the increases in plasma levels of propiomelanocortin-derived peptides and prolactin.  Neuroendocrinology. 1987;46:222-230.

80. Dallman MF, Strack A, Akana S, et al.  Feast and famine: critical role of glucocorticoids with insulin in daily energy flow.   Front Neuroendocrinol. 1993;14:303-347.

81. Bruno RL, Sapolsky R, Zimmerman JR, Frick NM.  The pathophysiology of a central cause of post-polio fatigue.   Ann NY Acad Sci. 1995;753:257-275.

82. Moodradian AD.  Geriatric neuroendocrinology.  In: Nemeroff CB, ed. Neuroendocrinology. Boca Raton, FL: CRC Press, 1992.

83. Miller LH, Kastin AJ, Sandman CA, et al.  Polypeptide influences on attention, memory and anxiety in man.  Pharmacol Biochem Behav. 1974;2:663-668.

84. Reinberg A, Briere L, Fraboulet G, et al.  Clinical chronobiology of ACTH 1-17.  Chronobiologia. 1981;8:101-115.

85. Strand FL, Cayer A, Gonzalez E, Stoboy H.  Peptide enhancement of neuromuscular function.  Pharmacol Biochem Beh. 1976;5(suppl 1):179-187.

86. Van Wimersma Greidanus TJ, de Wied D.  Effects of systemic and intracerebral administration of two opposite acting ACTH-related peptides on extinction of conditioned avoidance behavior.  Neuroendocrinology. 1971;7:291-301.

87. Demitrack MA, Dale JK, Straus SE, et al.  Evidence for impaired activation of the hypothalamic-pituitary-adrenal axis in patients with chronic fatigue syndrome.  J Clin Endocrinol Metab. 1991;73:1224-1234.

88. Majeed T, Dinan TG, Behan PO.  Ipsaprione induced ACTH release--Evidence of impaired activation of the HPA axis in patients with CFS.  Proceedings of the First World Congress of Chronic Fatigue Syndrome and Related Disorders, Brussels, 1995:103.

89. Bruno RL, Frick NM, Creange SJ, et al.  Polioencephalitis and the brain fatigue generator model of post-viral fatigue syndromes.  J Chronic Fatigue Syndrome. 1996;2:5-27.

90. Costa DC, Tannock C, Brostoff J.  Brainstem perfusion is impaired in chronic fatigue syndrome.  Q J Med. 1995;88:767-773.

91. Tavio M, Chierochetti F, Bianchini B, et al.  Brain positron emission tomography (PET) in chronic fatigue syndrome: a useful tool for differential diagnosis.  Proceedings of the American Association for Chronic Fatigue Syndrome Conference. San Francisco: AACFS, 1996.

92. Rowe PC, Bou-Holaigah I, Kan JS, Calkins H.  Is neurally mediated hypotension an unrecognized cause of chronic fatigue syndrome?  Lancet. 1995;345:623-624.

93. Bou-Holaigah I, Rowe PC, Kan JS, Calkins H.  The relationship between neurally mediated hypotension and the chronic fatigue syndrome.  JAMA. 1995;274:961-967.

94. Lapp CW.  NMH, POTS and CFS. Proceedings of the American Association for Chronic Fatigue Syndrome Conference. San Francisco: AACFS, 1996.

95. Bruno RL.  Chronic fatigue, fainting and autonomic dysfunction: Further similarities between post-polio fatigue and chronic fatigue syndrome?  J Chronic Fatigue Syndrome. 1997;3:107-117.

96. Bruno RL.  Fainting and fatigue: causation or coincidence?  CFIDS Chronicle. 1996;9:37-39.

97. McQuarie I.  The evolution of signs and symptoms of poliomyelitis.  In: Poliomyelitis. Philadelphia: Lippincott, 1949:57-61.

98. Bakheit A.  Abnormal arginine-vasopressin secretion and water metabolism in patients with post-viral fatigue syndrome.  Acta Neurol Scand. 1993;87:234-238.

99. Pan J-T.  Neuroendocrine functions of dopamine. In: Stone TW, ed. CNS Neurotransmitters and Neuromodulators: Dopamine. Boca Raton, FL: CRC Press, 1996:213-232.

100. Valentino DA, Arruda JE, Gold SM.  Comparison of QEEG and response accuracy in good vs poor performers during a vigilance task. Int J Psychophysiol. 1993;15:123-134.

101. O'Hanlon JF, Beatty J.  Concurrence of electroencephalographic and performance changes during a simulated radar watch and some implications for the arousal theory of vigilance.  In: Mackie RR, ed. Vigilance. New York: Plenum Press, 1977:189-201.

102. Bruno RL, Creange SJ, Zimmerman JR, Frick NM.  Elevated plasma prolactin and EEG slow wave power in post-polio fatigue: implications for a dopamine deficiency underlying chronic fatigue syndromes.  J Chronic Fatigue Syndrome. 1998;4:61-76.

103. Bruno RL.  The psychology and psychology of the post-polio brain.  Keynote address, International Post-Polio Conference, Calgary: October, 1997.

104. Marcel B, Komaroff AL, Fagioli LR, et al.  Cognitive deficits in patients with chronic fatigue syndrome.  Biol Psychiatry. 1996;40:535-541.

105. Bruno RL, Zimmerman JR, Creange SJ, Lewis T, Molzen T, Frick NM.  Bromocriptine in the treatment of post-polio fatigue: a pilot study with implications for the pathophysiology of fatigue.  Am J Phys Med Rehabil. 1996;75:340-347.

106. Fagan D, Scott DD, Mitchell M, Tiplady B.  Effects of remoxipride on measures of psychological performance in healthy volunteers. Psychopharmacology. 1991;105:225-229.

107. Gear JHS.  Non polio causes of polio-like paralytic syndrome.  Rev Infect Dis. 1984;66:379-382.

108. Shindarov LM, Chumakov MP, Voroshilava MK, et al.  Epidemiological, clinical, and pathomorphological characteristics of epidemic poliomyelitis-like disease caused by enterovirus 71.  J Hygiene Epidemiol Microbiol. 1979;3:284-295.

109. Dowsett EG.  Human enteroviral infections.  J Hosp Infect. 1988;11:103-115.

110. Heathfield KWG, Pilsworth R, Wall BJ, Corsellis JAN.  Coxsackie B5 infection in Essex, 1965, with particular reference to the nervous system.  Q J Med. 1967;36:579-595.

111. Vorashilova MK, Chumakov MP.  Poliomyelitis-like properties of AB-IV coxsackie A-7 group of viruses.  Prog Med Virol. 1959;21:106-110.

112. Grist NR.  Type A7 Coxsackie (Type IV poliomyelitis) viral infection in Scotland.  J Hygiene (Cambridge). 1962;60:323-325.

113. Tuteja U, Pandya G, Bharagava R, et al.  Enterovirus specific IgM responses in children with acute and chronic paralytic syndrome.  J Trop Med Hyg. 1995;98:367-372. 

 

 

THE AMERICAN JOURNAL OF MEDICINE.

Recent Developments in Chronic Fatigue Syndrome

September 28, 1998  Volume 105 (3A)

 

 

====================================================================== 

The Committee for Justice

and Recognition of Myalgic Encephalomyelitis

 

Visit these pages

 

ME: The Record of Epidemics => http://www.oocities.org/tcjrme/CurrentTopics3.html

 

The Neurology of ME => http://www.oocities.org/tcjrme/fundamentals6.html

 

The Fundamentals Library =>  http://www.oocities.org/tcjrme/fundamentals.html 

   Diagnosis, Metabolism, Immunology 

 

 

TCJRME Home Page; http://www.oocities.org/tcjrme  

 

 

====================================================================

Protect yourself - Learn about ME - Educate your doctors - Alert the Public

====================================================================

 

 

Poliomyelitis and Myalgic Encephalomyelitis

 

 

 

TCJRME     F - 11

 

/